In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents

European Journal of Radiology

Volumn 81, Issue 10, 2012, Pages 2562-2567

  Langer, R D ^a   Lorke, D E ^b   Neidl Van Gorkom, K F ^a   Petroianu, G ^b   Azimullah, S ^a   Nurulain, S M ^a   Singh, S ^a   Fuchsjager M ^c  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c AL AIN HOSPITAL   (United Arab Emirates)

Author keywords

Animal studies; Gadolinium based contrast agents; Nephrogenic systemic fibrosis

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; HISTOPATHOLOGY; LONG TERM EXPOSURE; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION;

ANIMALS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GADOLINIUM; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; NEPHROGENIC FIBROSING DERMOPATHY; RATS; RATS, WISTAR;

EID: 84865250071     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2011.10.032     Document Type: Article

References (58)

1. S.E. Cowper, H.S. Robin, and S.M. Steinberg Scleromyxoedema-like cutaneous diseases in renal-dialysis patients Lancet 356 2000 1000 1001
2. S.E. Cowper, L.D. Su, and J. Bhawan Nephrogenic fibrosing dermopathy Am J Dermopathol 23 2001 383 393
3. S.E. Cowper Nephrogenic fibrosing dermopathy: the first 6 years Curr Opin Rheumatol 15 2003 785 790
4. T. Schmook, K. Budde, and C. Ulrich Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy Nephrol Dial Transplant 20 2005 220 222
5. Cowper SE. Nephrogenic fibrosing dermopathy [NFD/NSF website]; 2001-2009. Available at http://www.icnfdr.org [accessed January 16, 2011].
6. D.M. DeHoratius, and S.E. Cowper Nephrogenic systemic fibrosis: an emerging threat among renal patients Semin Dial 19 2006 191 194
7. E. Kanal, D.R. Broome, and D.R. Martin Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update Radiology 246 2008 11 14
8. H.S. Thomsen ESUR guideline: gadolinium-based contrast agents and nephrogenic systemic fibrosis Eur Radiol 17 2007 2692 2696
9. E. Altun, D.R. Martin, and R. Wertman Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy-report from two U.S. universities Radiology 253 2009 689 696
10. M. Heinrich, and M. Uder Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents - a status paper Fortschr Roentgenstr 179 2007 613 617
11. P.H. Kuo, E. Kanal, and A.K. Abu-Alfa Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis Radiology 242 2007 647 649
12. T. Leiner, C.U. Herborn, and M. Goyen Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide Eur Radiol 17 2007 1921 1923
13. P. Marckmann, L. Skov, and K. Rossen Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging J Am Soc Nephrol 17 2006 2359 2362
14. M.A. Perazella Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol 2 2007 200 202
15. M.A. Perazella, and R.A. Rodby Gadolinium use in patients with kidney disease: a cause for concern Semin Dial 20 2007 179 185
16. M.R. Prince, H. Zhang, and M. Morris Incidence of nephrogenic systemic fibrosis at two large medical centers Radiology 248 2008 807 816
17. E.A. Sadowski, L.K. Bennett, and M.R. Chan Nephrogenic systemic fibrosis: risk factors and incidence estimation Radiology 243 2007 148 157
18. H.S. Thomsen Gadolinium-based contrast media may be nephrotoxic even at approved doses Eur Radiol 14 2004 1654 1656
19. H.S. Thomsen Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide Eur Radiol 16 2006 2619 2621
20. H.S. Thomsen European Society of Urogenital Radiology guidelines on all contrast media application Curr Opin Urol 17 2007 70 76
21. H.S. Thomsen, S.K. Morcos, and P. Dawson Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol 61 2006 905 906
22. R.A. Vitti Gadolinium-based contrast agents and nephrogenic systemic fibrosis Radiology 250 2009 959 960
23. R. Wertman, E. Altun, and D.R. Martin Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities Radiology 248 2008 799 806
24. L.P. Golding, and J.M. Provenzale Nephrogenic systemic fibrosis: possible association with a predisposing infection Am J Roentgenol 190 2008 1069 1075
25. FDA. Gadolinium-based contrast agents [website]. Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm142882.htm [accessed January 16, 2011].
26. M. Maloo, P. Abt, and R. Kashyap Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update Am J Transplant 6 2006 2212 2217
27. F.A. Mendoza, C.M. Artlett, and N. Sandorfi Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature Semin Arthritis Rheum 35 2006 238 249
28. R.D. Swartz, L.J. Crofford, and S.H. Phan Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure Am J Med 114 2003 563 572
29. W.W. Ting, M.S. Stone, and K.C. Madison Nephrogenic fibrosing dermopathy with systemic involvement Arch Dermatol 139 2003 903 906
30. M. Edward, J.A. Quinn, and S. Mukherjee Gadodiamide contrast agent "activates" fibroblasts: a possible cause of nephrogenic systemic fibrosis J Pathol 214 2008 584 593
31. T.A. Hope, W.A. High, and P.E. LeBoit Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron Radiology 253 2009 390 398
32. I.M. Wahba, K. White, and M. Meyer The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy - report of two cases and review of the literature Nephrol Dial Transplant 22 2007 631 636
33. H.H. Abujudeh, R. Kaewlai, and A. Kagan Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients Radiology 253 2009 81 89
34. D.R. Broome, M.S. Girguis, and P.W. Baron Gadolinium-associated nephrogenic systemic fibrosis: why radiologists should be concerned Am J Roentgenol 188 2007 588 592
35. K. Juluru, J. Vogel-Claussen, and K.J. Macura MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety Radiographics 29 2009 9 22
36. J. Perez-Rodriguez, S. Lai, and B.D. Ehst Nephrogenic systemic fibrosis: incidence, associations and effect of risk factor assessment - report of 33 cases Radiology 250 2009 371 377
37. T.A. Collidge, P.C. Thomson, and P.B. Mark Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort Radiology 245 2007 168 175
38. D. Grant, H. Johnsen, and A. Juelsrud Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis Acta Radiol 50 2009 156 169
39. T. Grobner Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic fibrosis? Nephrol Dial Transplant 21 2006 1104 1108
40. S.K. Morcos Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 80 2007 73 76
41. H. Pietsch, P. Lengsfeld, and G. Jost Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents Eur Radiol 19 2009 1417 1424
42. H. Pietsch, and T. Steger-Hartmann Nephrogenic systemic fibrosis: pre-clinical investigations of cytokine status and the role of macrophages Eur Radiol 19 S1 2009 285
43. M.A. Sieber, P. Lengsfeld, and J. Walter Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand J Magn Reson Imaging 27 2008 955 962
44. M.A. Sieber, P. Lengsfeld, and T. Frenzel Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions Eur Radiol 18 2008 2164 2173
45. M.A. Sieber, H. Pietsch, and J. Walter A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media Invest Radiol 43 2008 65 75
46. A.S. Boyd, J.A. Zic, and J.L. Abraham Gadolinium deposition in nephrogenic fibrosing dermopathy J Am Acad Dermatol 56 2007 27 30
47. W.A. High, R.A. Ayers, and J. Chandler Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis J Am Acad Dermatol 56 2007 21 26
48. W.A. High Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis J Am Acad Dermatol 56 2007 710 712
49. C. Thakral, and J.L. Abraham Automated scanning electron microscopy and X-ray microanalysis for in situ quantification of gadolinium deposits in skin J Electron Microsc 56 2007 181 187
50. C.D. Wiginton, B. Kelly, and A. Oto Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue Am J Roentgenol 190 2008 1060 1068
51. Z.-P. Zhang, Y.-H. Tian, and R. Li The comparison of the normal blood biochemical values of Wistar rats with different age and sex Asian J Drug Metabol Pharmacy 4 2004 215 218
52. C. Kucher, J. Steere, and R. Elenitsas Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure J Am Acad Dermatol 54 2006 S31 S34
53. Portnoy S, Bishop J, Dazai J, et al. Characterization of signal enhancement following the intraperitoneal injection of Gadolinium based contrast agents. ISMRM Abstract Book 2008.
54. S. Heckl, T. Naegele, and M. Herrmann Experimental autoimmune encephalomyelitis (EAE): lesion visualization on a 3 tesla clinical whole-body system after intraperitoneal contrast injection Fortschr Roentgenstr 176 2004 1549 1554
55. Lam KC. MRI tumor characterization in animal models of liver cancer. The University of Hong Kong, Medical Engineering Final Year Project 06; 2006.
56. E.S. Harpur, D. Worah, and P.A. Hals Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent Invest Radiol 28 S1 1993 28 43
57. T. Frenzel, P. Lengsfeld, and H. Schirmer Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 °C Invest Radiol 43 2008 817 828
58. S.K. Morcos Validity of the animal models for nephrogenic systemic fibrosis Invest Radiol 43 2008 33